There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come.
Peregrine Pharmaceuticals (NASDAQ: PPHM ) kicks off the new trading week with its latest quarterly report on Monday afternoon. Peregrine is researching monoclonal antibodies for the treatment and diagnosis of cancer.
No one's holding out for a profit. Peregrine is still at least a couple of years away from profitability and meaningful revenue. However, every quarterly conference call affords Peregrine the chance to update investors on its progress.
Bank of America (NYSE: BAC ) becomes the third of the "too big to fail" banks to report this earnings season when it steps up with updated financials on Wednesday. The first bank to report, Wells Fargo, posted a sharp drop in mortgage revenue on Friday, so naturally investors will be keeping an eye on how Bank of America is holding up on that front.
Advanced Micro Devices (NASDAQ: AMD ) checks in with its quarterly results on Thursday. AMD has done an admirable job of moving beyond its microprocessor business for PCs with its chips now powering all three of the world's largest video game consoles. The new strategy's been paying off for AMD. After a brief run in the red, AMD has come through with three consecutive profitable quarters. It hopes to stretch that streak to four quarters on Thursday afternoon.
The last day of the trading week is typically a quiet one, but that certainly isn't the case when earnings season rolls around. Several notable companies will be updating the market on their fiscal performances, but the biggest name here will be General Electric (NYSE: GE ) in the morning. Analysts see revenue and earnings per share climbing 3% and 8%, respectively.
Trend Tracker: Warren Buffett: This new technology is a "real threat"
At the recent Berkshire Hathaway annual meeting, Warren Buffett admitted that an emerging technology is threatening the Oracle of Omaha's bread and butter. And it's no long a question of if, but when, according to the industry's foremost research firm. Find out how you can cash in on this technology before the crowd catches on, by jumping on to one company that could get you the biggest piece of the action. All the details are laid out in a new free investor alert from The Motley Fool. Click here now to learn more!
Editor's note: A previous version of this article incorrectly suggested an impending regulatory catalyst for MannKind. The passage has been removed. The Motley Fool regrets the error.